Peripheral Drug Eluting Stent Market Report: Trends, Forecast and Competitive Analysis to 2031

Peripheral Drug Eluting Stent Market Trends and Forecast

The future of the global peripheral drug eluting stent market looks promising with opportunities in the hospital and mobile surgery center markets. The global peripheral drug eluting stent market is expected to grow with a CAGR of 7.9% from 2025 to 2031. The major drivers for this market are the increasing prevalence of peripheral artery disease and the growing incidence of diabetes & cardiovascular diseases.

• Lucintel forecasts that, within the type category, biodegradable stent is expected to witness higher growth over the forecast period.

• Within the application category, mobile surgery center is expected to witness the highest growth.

• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Peripheral Drug Eluting Stent Market

The peripheral drug eluting stent market is undergoing notable transformations, influenced by emerging trends that are reshaping the industry landscape. These trends encompass technological advancements, demographic shifts, and evolving healthcare practices. Understanding these trends is essential for stakeholders aiming to navigate the dynamic peripheral drug eluting stent market effectively.

• Technological Advancements: The development of bioresorbable stents represents a significant technological advancement in the peripheral drug eluting stent market. These stents gradually dissolve after fulfilling their purpose, reducing long-term complications associated with permanent implants. This innovation enhances patient safety and aligns with the growing preference for minimally invasive procedures.

• Aging Population: Globally, the aging population is increasing, leading to a higher incidence of peripheral artery disease (PAD). This demographic shift drives the demand for effective treatments like drug-eluting stents, prompting healthcare systems to adapt and accommodate the growing need for vascular interventions.

• Focus on Outpatient Procedures: There is a growing emphasis on performing vascular interventions in outpatient settings, driven by the need to reduce healthcare costs and improve patient convenience. This trend necessitates the development of stent technologies that support quicker recovery times and shorter hospital stays.

• Integration of Imaging Technologies: The integration of advanced imaging technologies, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), into stent procedures enhances precision and outcomes. These imaging modalities allow for better assessment of arterial conditions, leading to more accurate stent placement and improved patient prognosis.

• Regulatory Changes: Evolving regulatory frameworks are influencing the peripheral drug eluting stent market, with agencies implementing stricter guidelines to ensure patient safety and product efficacy. Manufacturers must adapt to these changes by enhancing their research and development processes and ensuring compliance with new standards. These emerging trends are collectively reshaping the peripheral drug eluting stent market by driving innovation, influencing healthcare delivery models, and prompting regulatory adaptations. Stakeholders must stay abreast of these developments to effectively navigate the evolving landscape and capitalize on emerging opportunities.

Recent Development in the Peripheral Drug Eluting Stent Market

The peripheral drug eluting stent market has experienced significant developments in recent years, driven by technological advancements, demographic shifts, and evolving healthcare practices. These changes have collectively enhanced patient outcomes and reshaped the market landscape.

• Introduction of Bioresorbable Stents: The development of bioresorbable stents marks a pivotal advancement in the peripheral drug eluting stent market. These stents gradually dissolve after providing structural support, reducing long-term complications associated with permanent implants. This innovation aligns with the growing preference for minimally invasive procedures and enhances patient safety.

• Advancements in Drug Coatings: Improvements in drug coatings have led to more effective prevention of restenosis. Enhanced drug formulations and delivery mechanisms ensure sustained release of medication, reducing the likelihood of arterial re-narrowing and improving long-term patient outcomes.

• Integration of Imaging Technologies: The incorporation of advanced imaging modalities, such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT), into stent procedures has improved precision in stent placement. These technologies allow for better assessment of arterial conditions, leading to optimized treatment strategies and enhanced patient outcomes.

• Focus on Patient-Centric Care: There is an increasing emphasis on patient-centric care in the peripheral drug eluting stent market. This approach involves tailoring treatment plans to individual patient needs, preferences, and risk profiles, leading to more personalized and effective interventions.

• Regulatory Changes: Evolving regulatory frameworks have impacted the peripheral drug eluting stent market. Agencies are implementing stricter guidelines to ensure patient safety and product efficacy. Manufacturers must adapt to these changes by enhancing their research and development processes and ensuring compliance with new standards. These developments are collectively reshaping the peripheral drug eluting stent market by driving innovation, influencing healthcare delivery models, and prompting regulatory adaptations. Stakeholders must stay abreast of these changes to effectively navigate the evolving landscape and capitalize on emerging opportunities.

Strategic Growth Opportunities in the Peripheral Drug Eluting Stent Market

The peripheral drug eluting stent market presents several strategic growth opportunities across key applications. Identifying and leveraging these opportunities is crucial for stakeholders aiming to expand their presence and enhance patient outcomes in this dynamic market.

• Treatment of Complex Lesions: Advancements in stent technology have enabled the effective treatment of complex peripheral lesions. Developing stents tailored for challenging anatomies can address unmet clinical needs and expand market reach.

• Management of Diabetic Patients: Diabetic patients are at a higher risk for peripheral artery disease (PAD). Designing DES specifically for this demographic can improve outcomes and tap into a growing patient population.

• Use in Below-the-Knee Interventions: Expanding the application of DES to below-the-knee procedures offers a significant growth avenue. This approach addresses critical limb ischemia and reduces amputation rates, meeting a vital clinical demand.

• Integration with Drug-Coated Balloons: Combining DES with drug-coated balloon therapies can enhance treatment efficacy. This synergistic approach offers a comprehensive solution for PAD management, providing a competitive edge.

• Adoption in Outpatient Settings: Developing DES suitable for outpatient procedures aligns with the shift towards cost-effective healthcare delivery. This strategy caters to patient preferences for minimally invasive treatments and shorter recovery times. By focusing on these strategic growth opportunities, stakeholders can drive innovation, improve patient outcomes, and achieve sustainable expansion in the peripheral drug eluting stent market.

Peripheral Drug Eluting Stent Market Driver and Challenges

The peripheral drug eluting stent market is influenced by various drivers and challenges, encompassing technological, economic, and regulatory factors. Understanding these elements is essential for stakeholders to navigate the market effectively and capitalize on growth opportunities. The factors responsible for driving the peripheral drug eluting stent market include: 1. Technological Advancements: Continuous innovations, such as the development of bioresorbable stents and improved drug coatings, enhance patient outcomes and expand treatment options. 2. Increasing Prevalence of Peripheral Artery Disease (PAD): The rising incidence of PAD, driven by factors like aging populations and lifestyle changes, boosts the demand for effective treatments like DES. 3. Growing Geriatric Population: An aging global population leads to a higher prevalence of vascular diseases, increasing the need for DES interventions. 4. Minimally Invasive Procedure Preference: Patients and healthcare providers favor minimally invasive treatments, positioning DES as a preferred option due to reduced recovery times and complications. 5. Healthcare Infrastructure Development: Improvements in healthcare facilities, especially in emerging markets, facilitate the adoption of advanced medical devices like DES. Challenges in the peripheral drug eluting stent market are: 1. High Costs: The expense of DES procedures can limit accessibility, particularly in regions with constrained healthcare budgets. 2. Regulatory Hurdles: Stringent approval processes and varying regulations across regions can delay product launches and increase compliance costs. 3. Competition from Alternative Therapies: Emerging treatments and technologies may offer alternative solutions, challenging the DES market's growth. The peripheral drug eluting stent market is shaped by a complex interplay of drivers and challenges. Technological innovations and demographic trends present significant growth opportunities, while economic and regulatory factors require strategic navigation. Stakeholders must address these challenges proactively to capitalize on the market's potential and improve patient care outcomes.

List of Peripheral Drug Eluting Stent Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peripheral drug eluting stent companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the peripheral drug eluting stent companies profiled in this report include-

• Boston Scientific

• Medtronic

• Abbot

• W. L. Gore & Associates

• iVascular SLU

• Meril Life Sciences

• Stentys

• Cordis

• Cook Medical

• MicroPort Endovascular MedTech

Peripheral Drug Eluting Stent Market by Segment

The study includes a forecast for the global peripheral drug eluting stent market by type, application, and region.

Peripheral Drug Eluting Stent Market by Type [Value from 2019 to 2031]:

• Metal Alloy Stent

• Biodegradable Stent

Peripheral Drug Eluting Stent Market by Application [Value from 2019 to 2031]:

• Hospital

• Mobile Surgery Center

• Others

Peripheral Drug Eluting Stent Market by Region [Value from 2019 to 2031]:

• North America

• Europe

• Asia Pacific

• The Rest of the World

Country Wise Outlook for the Peripheral Drug Eluting Stent Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below image highlights recent developments by major peripheral drug-eluting stent producers in key regions: the USA, China, India, Japan, and Germany

• United States: The U.S. peripheral drug eluting stent market has witnessed substantial growth, primarily due to the rising incidence of PAD among its aging population. Advancements in stent technology, such as the development of bioresorbable stents, have enhanced patient outcomes by reducing restenosis rates. The U.S. market is expected to continue its growth trajectory, driven by technological innovations and increasing healthcare expenditure.

• China: China's peripheral drug eluting stent market is projected to reach approximately USD 771.4 million by 2030, with a compound annual growth rate (CAGR) of 9.6% from 2024 to 2030. This growth is attributed to the rising prevalence of cardiovascular diseases and increased healthcare investments. Government initiatives to improve healthcare infrastructure and access have also contributed to market expansion.

• Germany: Germany has experienced steady growth in its peripheral drug eluting stent market, driven by a high prevalence of PAD and a robust healthcare system. The adoption of advanced stent technologies, including drug-eluting and bioresorbable stents, has improved patient outcomes. Germany's focus on research and development continues to foster innovation in the stent market.

• India: India's peripheral drug eluting stent market is expected to reach approximately USD 539.8 million by 2030, with a CAGR of 9.9% from 2024 to 2030. Factors contributing to this growth include an increasing prevalence of PAD, a growing geriatric population, and improvements in healthcare infrastructure. The adoption of advanced stent technologies is also on the rise, enhancing treatment outcomes.

• Japan: Japan's peripheral drug eluting stent market has seen moderate growth, influenced by its aging population and high incidence of PAD. The country's advanced healthcare system and focus on technological innovation have led to the adoption of cutting-edge stent technologies. Ongoing research and development efforts are expected to further drive market growth.

Features of the Global Peripheral Drug Eluting Stent Market

Market Size Estimates: Peripheral drug eluting stent market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions. Segmentation Analysis: Peripheral drug eluting stent market size by type, application, and region in terms of value ($B). Regional Analysis: Peripheral drug eluting stent market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the peripheral drug eluting stent market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peripheral drug eluting stent market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the growth forecast for peripheral drug eluting stent market? Answer: The global peripheral drug eluting stent market is expected to grow with a CAGR of 7.9% from 2025 to 2031. Q2. What are the major drivers influencing the growth of the peripheral drug eluting stent market? Answer: The major drivers for this market are the increasing prevalence of peripheral artery disease and the growing incidence of diabetes & cardiovascular diseases. Q3. What are the major segments for peripheral drug eluting stent market? Answer: The future of the peripheral drug eluting stent market looks promising with opportunities in the hospital and mobile surgery center markets. Q4. Who are the key peripheral drug eluting stent market companies? Answer: Some of the key peripheral drug eluting stent companies are as follows:

• Boston Scientific

• Medtronic

• Abbot

• W. L. Gore & Associates

• iVascular SLU

• Meril Life Sciences

• Stentys

• Cordis

• Cook Medical

• MicroPort Endovascular MedTech Q5. Which peripheral drug eluting stent market segment will be the largest in future? Answer: Lucintel forecasts that, within the type category, biodegradable stent is expected to witness higher growth over the forecast period. Q6. In peripheral drug eluting stent market, which region is expected to be the largest in next 5 years? Answer: In terms of region, APAC is expected to witness the highest growth over the forecast period. Q7. Do we receive customization in this report? Answer: Yes, Lucintel provides 10% customization without any additional cost.